Clinical Trial Finds Lyme Disease Vaccine Safe and Effective

A recent Precisions Vaccinations article discussed a new vaccine that can prevent the tick-transmitted disease that can cause permanent damage to joints and nerves. The Lyme disease vaccine, developed by Valneva, works by stopping Lyme-causing bacteria in ticks from penetrating the bloodstream. 

A press statement published on July 22nd noted the VLA15 vaccine candidate proved immunogenic across all groups tested. Furthermore, higher doses elicited high antibody responses across all groups as well. Valneva is working with Pfizer to develop and commercialize the vaccine, which should be available within 5 years.